Celgene Drug Misses Mark in Spinal Arthritis Study

Read below for more on this story.

Jul 9, 2014 at 2:00PM

Celgene branched out from its blood cancer roots earlier this year when it won an FDA nod for an oral arthritis drug called apremilast (Otezla). But the Summit, NJ-based company's plan to turn that drug into a franchise took a hit on Wednesday after it failed a late-stage trial for a form of arthritis affecting the spine.

Celgene (NASDAQ:CELG) said today that apremilast failed a Phase 3 study in what's known as ankylosing spondylitis, a painful form of arthritis that causes inflammation of the vertebrae. Apremilast didn't improve patients' symptoms in a statistically significant way—Celgene's goal had been to significantly reduce patients' symptoms by 20 percent after 16 weeks, compared to a placebo. Celgene released only top-line results from the study today. It'll provide more details from the trial at a future medical meeting.

The news is a setback for Celgene, albeit not necessarily an unexpected one—shares of Celgene were down only 1.6 percent in pre-market trading on Thursday, and RBC Capital Markets analyst Michael Yee wrote in a note earlier this month that investors "appear[ed] to have low expectations" for the trial.

Celgene is best known for its blood cancer drugs like thalidomide, but has been pushing the development of an inflammation and immunology franchise, with apremilast—an oral drug that works by inhibiting the enzyme phosphodiesterase 4—as its anchor. Celgene won FDA approval of apremilast in psoriatic arthritis in March, and viewed it as a stepping stone to prove the drug could be effective at treating several other inflammatory disorders that are commonly treated with injectable biologics. Ankylosing spondylitis was one of its shots at expanding the franchise, along with psoriasis. The FDA could approve apremilast in psoriasis later this year.

While today's study failed, Celgene says it hasn't given up hope in ankylosing spondylitis. The company is pointing to efficacy it's seen in a "large" subset of patients with early stage disease after 24 weeks of treatment with apremilast, and said it will collect MRI  data on a subgroup of patients after 52 weeks of treatment. It'll also perform radiographs on all patients in the study after 104 weeks. Celgene might start another Phase 3 trial after it collects more data.

"Ankylosing spondylitis is a chronic, debilitating disease, and despite advances over the last 15 years, there remains significant unmet need for a safe, effective, oral therapy—especially for patients early in the progression of their disease," said Scott Smith, Celgene's head of inflammation and immunology.

Celgene and Wall Street, meanwhile, haven't seen eye to eye on apremilast's potential. Celgene has said it expects the drug to bring in between $1.5 billion and $2 billion in sales in 2017. By comparison, in a recent report, EP Vantage estimated about $1.2 billion in sales in 2018. Consensus analyst estimates have the drug bringing in $130 million this year.

Leaked: This coming blockbuster will make every biotech jealous
The best biotech investors consistently reap gigantic profits by recognizing true potential earlier and more accurately than anyone else. Let me cut right to the chase. There is a product in development that will revolutionize not just how we treat a common chronic illness, but potentially the entire health industry. Analysts are already licking their chops at the sales potential. In order to outsmart Wall Street and realize multi-bagger returns you will need The Motley Fool's new free report on the dream-team responsible for this game-changing blockbuster. CLICK HERE NOW.

This article originally appeared on Xconomy, along with:

Ben Fidler has no position in any stocks mentioned. The Motley Fool recommends Celgene. Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.

1 Key Step to Get Rich

Our mission at The Motley Fool is to help the world invest better. Whether that’s helping people overcome their fear of stocks all the way to offering clear and successful guidance on complicated-sounding options trades, we can help.

Feb 1, 2016 at 4:54PM

To be perfectly clear, this is not a get-rich action that my Foolish colleagues and I came up with. But we wouldn't argue with the approach.

A 2015 Business Insider article titled, "11 websites to bookmark if you want to get rich" rated The Motley Fool as the #1 place online to get smarter about investing.

"The Motley Fool aims to build a strong investment community, which it does by providing a variety of resources: the website, books, a newspaper column, a radio [show], and [newsletters]," wrote (the clearly insightful and talented) money reporter Kathleen Elkins. "This site has something for every type of investor, from basic lessons for beginners to investing commentary on mutual funds, stock sectors, and value for the more advanced."

Our mission at The Motley Fool is to help the world invest better, so it's nice to receive that kind of recognition. It lets us know we're doing our job.

Whether that's helping the entirely uninitiated overcome their fear of stocks all the way to offering clear and successful guidance on complicated-sounding options trades, we want to provide our readers with a boost to the next step on their journey to financial independence.

Articles and beyond

As Business Insider wrote, there are a number of resources available from the Fool for investors of all levels and styles.

In addition to the dozens of free articles we publish every day on our website, I want to highlight two must-see spots in your tour of fool.com.

For the beginning investor

Investing can seem like a Big Deal to those who have yet to buy their first stock. Many investment professionals try to infuse the conversation with jargon in order to deter individual investors from tackling it on their own (and to justify their often sky-high fees).

But the individual investor can beat the market. The real secret to investing is that it doesn't take tons of money, endless hours, or super-secret formulas that only experts possess.

That's why we created a best-selling guide that walks investors-to-be through everything they need to know to get started. And because we're so dedicated to our mission, we've made that available for free.

If you're just starting out (or want to help out someone who is), go to www.fool.com/beginners, drop in your email address, and you'll be able to instantly access the quick-read guide ... for free.

For the listener

Whether it's on the stationary exercise bike or during my daily commute, I spend a lot of time going nowhere. But I've found a way to make that time benefit me.

The Motley Fool offers five podcasts that I refer to as "binge-worthy financial information."

Motley Fool Money features a team of our analysts discussing the week's top business and investing stories, interviews, and an inside look at the stocks on our radar. It's also featured on several dozen radio stations across the country.

The hosts of Motley Fool Answers challenge the conventional wisdom on life's biggest financial issues to reveal what you really need to know to make smart money moves.

David Gardner, co-founder of The Motley Fool, is among the most respected and trusted sources on investing. And he's the host of Rule Breaker Investing, in which he shares his insights into today's most innovative and disruptive companies ... and how to profit from them.

Market Foolery is our daily look at stocks in the news, as well as the top business and investing stories.

And Industry Focus offers a deeper dive into a specific industry and the stories making headlines. Healthcare, technology, energy, consumer goods, and other industries take turns in the spotlight.

They're all informative, entertaining, and eminently listenable ... and I don't say that simply because the hosts all sit within a Nerf-gun shot of my desk. Rule Breaker Investing and Answers contain timeless advice, so you might want to go back to the beginning with those. The other three take their cues from the market, so you'll want to listen to the most recent first. All are available at www.fool.com/podcasts.

But wait, there's more

The book and the podcasts – both free ... both awesome – also come with an ongoing benefit. If you download the book, or if you enter your email address in the magical box at the podcasts page, you'll get ongoing market coverage sent straight to your inbox.

Investor Insights is valuable and enjoyable coverage of everything from macroeconomic events to investing strategies to our analyst's travels around the world to find the next big thing. Also free.

Get the book. Listen to a podcast. Sign up for Investor Insights. I'm not saying that any of those things will make you rich ... but Business Insider seems to think so.


Compare Brokers